| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 河南太龙药业股份有限公司创立于1993年，主要业务为药品制造和药品研发服务，具体包含药品制剂、中药饮片、药品研发服务和药品药材流通四个板块的业务。主要产品包括双黄连口服液系列、双金连合剂、丹参口服液、小儿清热止咳口服液、小儿复方鸡内金咀嚼片、石杉碱甲片等。其中，双黄连口服液(浓缩型)、双黄连口服液(儿童型)、双金连合剂及小儿复方鸡内金咀嚼片为公司独家产品。 1999年，太龙药业股票在上海证券交易所隆重上市，成为河南省医药行业的首家上市公司。经过二十余年的发展，太龙药业先后间接参股、控股了十数家子(分)公司，涉及领域涵盖医药制造、药品研发、资本运作等相关领域，主要经济指标在河南省医药行业中位居前列。 公司以市场需求为导向精细组织生产。在生产过程中严格按照GMP要求，全方面实行生产全过程质量管理，按照药品药典标准、药品注册标准和企业内控标准进行检验，确保安全生产、药品质量稳定。 公司是经国家科学技术部认证的国家火炬计划重点高新技术企业，是国家发改委评定的“国家高技术产业化示范工程”，拥有国家人事部批准的博士后工作站及享受国务院特殊贡献津贴的学术带头人;建立了由国内外顶尖科研专家领衔、近千人组成的研发团队，拥有先进的科研检测设备，研发技术实力国内领先;拥有一支由具备行业资深经验的高端管理人才和业务能力强、扎根一线、服务终端的技术、营销人才组成的团队;中药饮片传统炮制工艺核心技术人员获得“中华老字号杰出工匠”荣誉称号。 公司主要采取“经销分销”的销售模式，建立了覆盖全国的营销网络，利用经销商的渠道资源和配送优势实现对等级医院、基层医疗机构和零售终端的覆盖，同时公司自有销售团队通过专业学术推广、品牌宣传、市场促销等方式加强对终端的服务和管理;公司还通过深化与各大连锁药店战略合作，拓展产品终端市场，不断扩大在行业和消费者中的品牌影响力。 | ||||||||||||||||||||||||
| Main Business | 研制、开发、生产和销售中成药和西药 | ||||||||||||||||||||||||
| Legal Representative | 尹辉 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 李念云 | ||||||||||||||||||||||||
| Solicitors | 河南仟问律师事务所 | ||||||||||||||||||||||||
| Auditors | 北京兴华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0371-67992262;0371-67982194 | ||||||||||||||||||||||||
| Fax No | 0371-67993600 | ||||||||||||||||||||||||
| Website | www.taloph.com | ||||||||||||||||||||||||
| taloph@taloph.com;600222@taloph.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 05/11/1999 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.077 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 2.751 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 3.042B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |